Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Organic mental disorders

2

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor alpha-1

2

Beta-2 adrenergic receptor

2

Glutamate NMDA receptor; Grin1/Grin2a

2

Glutamate NMDA receptor; Grin1/Grin2b

2

Glutamate NMDA receptor; Grin1/Grin2c

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1955

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

U.S. Vitamin

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

ChEMBL

2

DRUG BANK

2

ECHA (EC/EINECS)

2

EPA CompTox

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

GENITO URINARY SYSTEM AND SEX HORMONES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OTHER GYNECOLOGICALS

1

PERIPHERAL VASODILATORS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER GYNECOLOGICALS

1

PERIPHERAL VASODILATORS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

2-amino-1-phenylethanol derivatives

1

Sympathomimetics, labour repressants

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

NYLIDRIN

695DKH33EI

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1955

Class (Stereo):

CHEMICAL (UNKNOWN)

Targets:

Beta-2 adrenergic receptor

Glutamate NMDA receptor; Grin1/Grin2a

Glutamate NMDA receptor; Grin1/Grin2c

Glutamate NMDA receptor; Grin1/Grin2b

Adrenergic receptor alpha-1

Conditions:

Organic mental disorders

Peripheral vascular disorders

Nylidrin (Buphenine, Arlidin) is a beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and prematur...

e labor. In peripheral vascular disorders, Arlidin (nylidrin HCl) increases walking ability and promotes healing of trophic ulcers. Nylidrin hydrochloride acts predominantly by beta-receptor stimulation. Beta stimulation with nylidrin has been demonstrated in a variety of isolated tissues from rabbits, guinea pigs and dogs. It has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat and in unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of actions is a greater blood supply to ischemic tissues, with usually minimal change in blood pressure. Arlidin may be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders. Short-term (3 months’ duration) and long-term (12 months’ duration) clinical studies have demonstrated a modest improvement in ability to perform general activities of daily living, self-care and in a capability for social interactions. The mechanism whereby nylidrin may provide relief of selected symptoms in some elderly patients with organic brain disorders is not known.

NYLIDRIN HYDROCHLORIDE

EC69E3PW7E

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1955

Class (Stereo):

CHEMICAL (MIXED)

Targets:

Beta-2 adrenergic receptor

Glutamate NMDA receptor; Grin1/Grin2a

Glutamate NMDA receptor; Grin1/Grin2c

Glutamate NMDA receptor; Grin1/Grin2b

Adrenergic receptor alpha-1

Conditions:

Organic mental disorders

Peripheral vascular disorders

Nylidrin (Buphenine, Arlidin) is a beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and prematur...

e labor. In peripheral vascular disorders, Arlidin (nylidrin HCl) increases walking ability and promotes healing of trophic ulcers. Nylidrin hydrochloride acts predominantly by beta-receptor stimulation. Beta stimulation with nylidrin has been demonstrated in a variety of isolated tissues from rabbits, guinea pigs and dogs. It has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat and in unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of actions is a greater blood supply to ischemic tissues, with usually minimal change in blood pressure. Arlidin may be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders. Short-term (3 months’ duration) and long-term (12 months’ duration) clinical studies have demonstrated a modest improvement in ability to perform general activities of daily living, self-care and in a capability for social interactions. The mechanism whereby nylidrin may provide relief of selected symptoms in some elderly patients with organic brain disorders is not known.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1